Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals.

Clinical Consultations™: Coordinating Care Between the Pulmonologist and Rheumatologist in Systemic Sclerosis-Interstitial Lung Disease

Release Date: September 25, 2020
Expiration Date: September 25, 2021

Activity Overview

Interstitial lung disease (ILD) is a frequent and debilitating complication of systemic sclerosis (SSc) with a complex pathophysiology. SSc-ILD is a pulmonary fibrosing disorder characterized by systemic inflammation, progressive scarring of the lungs, and eventual respiratory failure. The presence of ILD in SSc is an important determinant of both disease severity and prognosis. Patients diagnosed with SSc need regular screening for ILD because early detection of progressive lung involvement is critical to starting pharmacologic intervention, which is more beneficial in the early stage of disease.

During this Clinical Consultations™, 2 expert faculty will review risk factors for SSc-ILD and the diagnostic tools used to determine which patients are at risk of disease progression. They will then discuss the latest evidence regarding treatment for SSc-ILD and the importance of a multispecialty approach to managing patients with this disease.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward rheumatologists, pulmonologists, dermatologists, and specialty nurse practitioners and physician assistants. Additional health care clinicians involved in the management of patients with SSc-ILD will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Review disease prevalence, pathophysiology, morbidity, and morality of SSc-ILD
  • Identify key risk factors and diagnostic tests to improve early symptom recognition and prognosis of SSc-ILD
  • Interpret key data on recently approved and emerging treatment options for SSc-ILD to improve clinical management
  • Describe best practices for effective communication and coordination between rheumatologists and pulmonologists to optimize patient outcomes

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Elizabeth R. Volkmann, MD, MS
Elizabeth R. Volkmann, MD, MS
Director, UCLA Scleroderma Center
Co-Director UCLA CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles

Disclosures: Grant/Research Support: Corbus, Forbius. Consultant: Boehringer Ingelheim, Forbius.

Lisa H Lancaster, MD
Lisa H Lancaster, MD
Professor of Medicine
Director, Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, Tennessee

Disclosures: Grant/Research Support: Celgene, Novartis, Bellerophon, Biogen, Galecto, Respirent, Galapagos, Boehringer Ingelheim, Genentech, BMS, Pliant. Consultant: Galapagos, United Therapeutics, AstraZeneca, Genentech, Devpro biopharma. Speaker’s Bureau: Genentech, Boehringer Ingelheim.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By